Product
Penpulimab
Aliases
AK105, Penpulimab injection, Penpulimab Injection
19 clinical trials
27 indications
Indication
Hepatocellular CarcinomaIndication
Colorectal CancerIndication
Advanced Malignant NeoplasmIndication
Nasopharyngeal CarcinomaIndication
Esophageal Squamous Cell CarcinomaIndication
Relapsed/Refractory LymphomaIndication
cancerIndication
Gastrointestinal DiseasesIndication
Stomach CancerIndication
Gastroesophageal Junction CancerIndication
Gastrointestinal NeoplasmsIndication
Head and Neck Squamous Cell CarcinomaIndication
Gynecological CancerIndication
Pancreatic CancerIndication
Pancreatic Adenocarcinoma MetastaticIndication
PheochromocytomaIndication
lung cancerIndication
TKI ResistanceIndication
EGFR Sensitive MutationIndication
AnlotinibIndication
PianzumabIndication
MetastaticIndication
Malignant PheochromocytomaIndication
ParagangliomaIndication
malignantIndication
Diffuse Large B-cell LymphomaIndication
Breast CancerClinical trial
Phase Ib Clinical Study Evaluating the Efficacy and Safety of TQB2223 Injection Combined With Penpulimab Injection in the Treatment of Advanced Hepatocellular CarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules as First-line Treatment for Advanced Hepatocellular Carcinoma.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase Ib Clinical Trial of TQB2928 Injection Combined With Penpulimab in the Treatment of Patients With Advanced Malignant Tumors.Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Relapsed or Refractory LymphomaStatus: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma, a Randomized, Controlled, Multicenter Clinical TrialStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Clinical Study of Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Single-arm, Open-label, Multi-cohort, Multi-center Phase II Clinical Study of Anlotinib Combined With Penpulimab in the Treatment of Recurrent or Metastatic Gynecological CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicenter Study of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as First-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer: PAAG.Status: Completed, Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Uncontrolled, Exploratory Phase 2 Trial of Irinotecan Plus Anlotinib or Further in Combination With Penpulimab as Second-line Treatment of Metastatic Colorectal Cancer (ZL-IRIAN)Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine (PAAG) as First-line Treatment for Advanced Metastatic Pancreatic Cancer: a Prospective, Multicenter, Single-arm, Phase 2 StudyStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small CellStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Study on the Efficacy and Safety of Penpulimab in the Treatment of Metastatic Pheochromocytoma/Paraganglioma Patients Who Fail to Other Systemic TreatmentStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
An Open, Single-arm, Multi-center Clinical Trial of Molecular Subtype-guided R-MINE+X Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status: Not yet recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Single-arm, Single-center Exploratory Clinical Study of Disitamab Vedotin Combined With Penpulimab as Neoadjuvant Therapy in the Treatment of HER2-low Early or Locally Advanced Breast CancerStatus: Not yet recruiting, Estimated PCD: 2024-07-31
Clinical trial
Neoadjuvant Immunotherapy in Combination With Chemotherapy in Resectable Head and Neck Cancer：A Randomized, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2025-12-01